Abstract:

Objectives:

To assess the feasibility of conducting a large clinical trial to evaluate the effectiveness of probiotics to reduce influenza and other respiratory virus infections in residents of long‐term and chronic care facilities (LTCFs).

Design:

Randomized, double‐blind, placebo‐controlled pilot trial.

Setting:

Fourteen nursing homes in Hamilton and surrounding region, Ontario, Canada.

Participants:

Nursing home residents aged 65 and older (N=209). Those who were taking immunosuppressives (steroids or other immunosuppressives) or had a hematological malignancy, structural heart disease, or gastroesophageal or intestinal injury and others at high risk of an endovascular infection were excluded.

Intervention:

Participants were randomized to receive study probiotics—2 capsules of Lactobacillus rhamnosus GG (estimated 10 billion colony forming units of L. rhamnosus GG per capsule) or placebo (calcium carbonate) daily for 6 months.

Measurements:

Laboratory‐confirmed respiratory viral infections.

Results:

One hundred ninety‐six individuals were included in the analysis: 100 in the probiotics group and 96 in the placebo group. Laboratory‐confirmed respiratory viral infections were observed in 14 (15.0%) residents in the probiotic group and 21 (22.9%) in the placebo group (hazard ratio=0.65, 95% confidence interval=0.32–1.31).

Conclusion:

A larger trial is warranted to determine whether probiotics reduce influenza and other respiratory virus infections in residents of LTCFs.

Reference:

https://onlinelibrary.wiley.com/doi/abs/10.1111/jgs.15396?af=R